PDCD1 and non-small cell lung carcinoma: Since PD-L1 DNA methylation and mRNA expression levels appear to be only weakly associated, our findings highlight the need for further research before PD-L1 DNA methylation can be implemented as a biomarker and drug target for measures to improve the effectiveness of PD-1/PD-L1 immunotherapy in NSCLC.